| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/13/2001 | CA2372931A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 09/12/2001 | EP1132401A1 HUMAN PROTEINS STAM2a AND STAM2b AND cDNAS ENCODING THESE MOLECULES |
| 09/12/2001 | EP1132392A1 Ketolide antibiotics |
| 09/12/2001 | EP1132390A2 Diazepinoindoles as phophodiesterase inhibitors |
| 09/12/2001 | EP1132389A1 New aza-indolyl derivatives for the treatment of obesity |
| 09/12/2001 | EP1132388A2 Hexahydropyrazolo[4,3-c]pyridine metabolites |
| 09/12/2001 | EP1132383A1 Novel agarofuan derivatives, their preparation, pharmaceutical composition containing them and their use as medicine |
| 09/12/2001 | EP1132382A1 3-Oxy-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadazine-1,1-dioxide derivatives having diuretic and/or natriuretic activity |
| 09/12/2001 | EP1132380A1 E-Isomeric fullerene derivatives |
| 09/12/2001 | EP1132351A1 Substrate with photocatalytic coating |
| 09/12/2001 | EP1132094A1 Percutaneously administrable preparations containing cerebral function activators |
| 09/12/2001 | EP1132093A1 Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing nf-kappa b inhibitors as the active ingredient |
| 09/12/2001 | EP1132090A1 Method for producing an agent for treating non-cancerous pathologies of the organism |
| 09/12/2001 | EP1132088A2 Method for inhibiting bone resorption |
| 09/12/2001 | EP1132087A1 Remedies for polycystic ovary syndrome |
| 09/12/2001 | EP1132086A2 Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
| 09/12/2001 | EP1132085A1 Drugs and reagents containing n-acyloxylated cycloalkyl compounds as the active ingredient |
| 09/12/2001 | EP1132084A1 Transdermal device for the slow release of soybean derived vegetable estrogens |
| 09/12/2001 | EP1132083A2 Use of zinc tranexamate in the treatment of diabetes |
| 09/12/2001 | EP1132082A1 Use of substances capable of blocking the production of glutamate for treating tension-type headache |
| 09/12/2001 | EP1132080A2 Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
| 09/12/2001 | EP1131633A2 Hiv-specific t-cell induction |
| 09/12/2001 | EP1131467A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 09/12/2001 | EP1131461A1 N-terminally truncated her-2/neu protein as a cancer prognostic indicator |
| 09/12/2001 | EP1131446A1 Coffea arabica mannanase |
| 09/12/2001 | EP1131440A2 Process for oxidising terpenes |
| 09/12/2001 | EP1131426A2 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides |
| 09/12/2001 | EP1131350A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 09/12/2001 | EP1131349A2 Potassium channel interactors and uses therefor |
| 09/12/2001 | EP1131340A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 09/12/2001 | EP1131337A1 Novel betulinic acid derivatives, processes for preparing such derivatives and its use as cancer growth inhibitors |
| 09/12/2001 | EP1131336A1 Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11 |
| 09/12/2001 | EP1131334A1 Use of core 2 glcnac transferase inhibitors in treating inflammation |
| 09/12/2001 | EP1131333A1 ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF |
| 09/12/2001 | EP1131331A1 13-membered azalides and their use as antibiotic agents |
| 09/12/2001 | EP1131327A1 Prostaglandin conjugates for treating or preventing bone disease |
| 09/12/2001 | EP1131323A1 Synthesis of acyclic nucleoside derivatives |
| 09/12/2001 | EP1131322A2 Dihydropyridine compounds and methods of use |
| 09/12/2001 | EP1131321A2 Indole derivatives and their use as serotonin receptor ligands |
| 09/12/2001 | EP1131316A2 Improved chemical process and pharmaceutical formulation |
| 09/12/2001 | EP1131315A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants |
| 09/12/2001 | EP1131314A1 Compounds having cytokine inhibitory activity |
| 09/12/2001 | EP1131312A1 Novel pyrimidine derivatives and processes for the preparation thereof |
| 09/12/2001 | EP1131311A1 2-acylamino-2-deoxy-glucono-1,5-lactones, method for obtaining same, compositions comprising them and uses |
| 09/12/2001 | EP1131310A1 Chrystals of 5- 6-(2-fluorobenzyl)oxy-2-naphthyl methyl]-2,4-thiazolidinedione |
| 09/12/2001 | EP1131308A1 New piperazine and piperidine compounds |
| 09/12/2001 | EP1131304A1 N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| 09/12/2001 | EP1131302A1 Substituted 4-amino-2-aryl-cyclopenta d]pyrimidines, their production and use and pharmaceuticalreparations containing same |
| 09/12/2001 | EP1131301A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 09/12/2001 | EP1131297A1 Certain substituted caprolactams, pharmaceutical compositions containing them and their use in treating tumors |
| 09/12/2001 | EP1131295A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 09/12/2001 | EP1131294A1 Quinoline derivatives as nk-2 and nk-3 receptor ligands |
| 09/12/2001 | EP1131293A1 1-aminoethylquinoline derivatives for treating urinary incontinence |
| 09/12/2001 | EP1131291A1 4-aroyl-piperidin-ccr-3 receptor antagonists iii |
| 09/12/2001 | EP1131290A1 Piperidine ccr-3 receptor antagonists |
| 09/12/2001 | EP1131288A1 Pyrrolidine derivatives-ccr-3 receptor antagonists |
| 09/12/2001 | EP1131135A1 Composition containing an analgesic and a xanthine cor a xanthine derivative |
| 09/12/2001 | EP1131113A1 Bioactive prostheses with immunosuppressive, antistenotic and antithrombotic properties |
| 09/12/2001 | EP1131106A1 Compositions and methods for producing vascular occlusion |
| 09/12/2001 | EP1131104A1 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
| 09/12/2001 | EP1131103A1 Stable amorphous amifostine compositions and methods for the preparation and use of same |
| 09/12/2001 | EP1131102A2 Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e |
| 09/12/2001 | EP1131101A1 Khellin preparation and the use thereof for topical therapy |
| 09/12/2001 | EP1131100A2 Therapeutic compositions for metabolic bone disorders or bone metastases |
| 09/12/2001 | EP1131099A2 Noninvasive vascular therapy |
| 09/12/2001 | EP1131093A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
| 09/12/2001 | EP1131090A2 Method of using pon-1 to decrease atheroma formation |
| 09/12/2001 | EP1131088A2 NF-$g(k)B ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES |
| 09/12/2001 | EP1131086A2 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
| 09/12/2001 | EP1131082A2 A method for treating tissue damaged from ischemia |
| 09/12/2001 | EP1131081A1 Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway |
| 09/12/2001 | EP1131076A1 Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic |
| 09/12/2001 | EP1131075A2 Use of phosphonoformic acid derivatives for treating infections |
| 09/12/2001 | EP1131074A1 Use of dehydroepiandrosterone for increasing the number of nmda receptors in a mammal |
| 09/12/2001 | EP1131073A1 Use of staurosporine derivatives for treating ocular neovascular diseases |
| 09/12/2001 | EP1131072A2 Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide |
| 09/12/2001 | EP1131071A1 Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption |
| 09/12/2001 | EP1131070A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 09/12/2001 | EP1131069A1 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 09/12/2001 | EP1131068A1 Compositions of and process for producing isotretinoin having low particle size |
| 09/12/2001 | EP1131067A1 Composition and use of rar antagonists for promoting chondrogenesis |
| 09/12/2001 | EP1131066A1 Oral creatine supplementation for treating or preventing muscle disuse syndrome |
| 09/12/2001 | EP1131065A2 Utilisation of dialkylfumarates |
| 09/12/2001 | EP1131064A2 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus |
| 09/12/2001 | EP1131063A2 Hyperforin as cytostatic agent and hyperforin ointment or cream as application form |
| 09/12/2001 | EP1131062A1 Injectable propofol formulations |
| 09/12/2001 | EP1131061A1 Agent for lowering prolactin |
| 09/12/2001 | EP1131060A2 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 09/12/2001 | EP1131059A1 Dry powder for inhalation |
| 09/12/2001 | EP1131058A1 Local delivery of drugs to the colon for local treatment of colonic diseases |
| 09/12/2001 | EP1131056A1 Particles based on polyamino-acid(s) and methods for preparing same |
| 09/12/2001 | EP1131052A1 Vaginally administrable progesterone-containing tablets and method for preparing same |
| 09/12/2001 | EP1131051A1 Pressurised metered dose inhalers (mdi) |
| 09/12/2001 | EP1131050A1 Galenic formulations fast disintegrating in the mouth and method for preparing same |
| 09/12/2001 | EP1131041A1 Novel fatty ammonium quaternary compositions |
| 09/12/2001 | EP1131039A2 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
| 09/12/2001 | EP1130980A1 Beverage for increasing the body's capacity to break down alcohol |
| 09/12/2001 | EP1130979A1 Calcium fortified juice-based nutritional supplement |
| 09/12/2001 | EP1130969A1 Murf2 polypeptides and polynucleotides |
| 09/12/2001 | EP1130966A1 Antiparasitic formulations |